Skip to main content

Table 1 Statements on non-invasive prenatal screening for fetal aneuploidy

From: Clinical performance of non-invasive prenatal served as a first-tier screening test for trisomy 21, 18, 13 and sex chromosome aneuploidy in a pilot city in China

InstitutionStatement
American College of Medical Genetics and Genomics(ACMG)NIPT is a screening test to identify pregnancies at risk for common autosomal aneuploidies (e.g., trisomy 21, 18, and 13). Some laboratories also offer screening for sex chromosome aneuploidie s[11, 12]. NIPT for fetal aneuploidy has arrived.
National Society of Genetic Counselors (NSGC)NIPT as an option for aneuploidy assessment in pregnancy: Peer-reviewed data currently supports NIPT as a screening tool for select population s[13].
Israeli Society of Medical Geneticists (ISMG)It may be advantageous to integrate NIPT with the current screening modalities as part of the screening program for fetal aneuploidy in Israe l[14, 15].
The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG)NIPT as a first-line screening test. Using NIPT on intermediate- or low-risk patients might be endorsed as a widely available option only when new data emerge and NIPT costs decreas e[16].